Assessing the effect of weight and weight loss in obese persons with type 2 diabetes

被引:10
作者
Curtis, Bradley [1 ]
Hayes, Risa P. [1 ]
Fehnel, Sheri [2 ]
Zografos, Laurie [2 ]
机构
[1] Eli Lilly & Co, Global Hlth Outcomes, Indianapolis, IN 46285 USA
[2] RTI Hlth Solut, Res Triangle Pk, NC 27703 USA
来源
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY | 2008年 / 1卷
关键词
health-related quality of life; obesity; type; 2; diabetes; weight loss; patient-reported outcomes;
D O I
10.2147/DMSO.S4237
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The objective of this study was to assess specifi c areas of life in which obesity affects individuals with type 2 diabetes mellitus (T2DM), and changes that obese persons with T2DM experience with weight loss of varying degrees. Thirty in- depth interviews were conducted in persons identifi ed as: age >= 40 years, diagnosed with T2DM for >= 2 years, on oral antihyperglycemic medications >3 months, BMI 30-35 kg/m(2), having attempted to lose weight in the last 2 years. Participants (60% female, mean age 53 years, 53% Caucasian, mean BMI 32.2 kg/ m(2)) agreed that 5% weight loss, while not refl ective of an ultimate goal, would be meaningful and important; benefi ts were expected to accrue in physical functioning, self-confi dence, blood glucose levels, and motivation to keep losing weight. Participants reported the greatest effect of weight loss on energy, physical activity, mobility, pain, and clothes/appearance. Participants reported weight affecting mood, with feelings of depression and frustration most commonly described. This research indicates that weight loss is likely to affect health-related quality of life in obese individuals with T2DM. Given the purported weight loss benefi ts of many emerging diabetic medications, it will be important to include measures of weight-related quality of life in future clinical trials of these agents.
引用
收藏
页码:13 / 23
页数:11
相关论文
共 21 条
  • [1] Standards of medical care in diabetes 2008
    不详
    [J]. DIABETES CARE, 2008, 31 : S12 - S54
  • [2] Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes
    Buse, JB
    Henry, RR
    Han, J
    Kim, DD
    Fineman, MS
    Baron, AD
    [J]. DIABETES CARE, 2004, 27 (11) : 2628 - 2635
  • [3] Cox D, 2002, INT J CLIN PRACT, P20
  • [4] Weight loss and quality of life improvement in obese subjects treated with sibutramine: A double-blind tandomized multicenter study
    Di Francesco, V.
    Sacco, T.
    Zamboni, M.
    Bissoli, L.
    Zoico, E.
    Mazzali, G.
    Minniti, A.
    Salanitri, T.
    Cancelli, F.
    Bosello, O.
    [J]. ANNALS OF NUTRITION AND METABOLISM, 2007, 51 (01) : 75 - 81
  • [5] Geographic variation in the prevalence of obesity, diabetes, and obesity-related behaviors
    Ford, ES
    Mokdad, AH
    Giles, WH
    Galuska, DA
    Serdula, MK
    [J]. OBESITY RESEARCH, 2005, 13 (01): : 118 - 122
  • [6] Grbich C., 2013, QUALITATIVE DATA ANA
  • [7] The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes
    Harder, H
    Nielsen, L
    Thi, TDT
    Astrup, A
    [J]. DIABETES CARE, 2004, 27 (08) : 1915 - 1921
  • [8] Hayes RP, 2006, DIABETES ED, V32, P1
  • [9] Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes
    Kim, Dennis
    MacConell, Leigh
    Zhuang, Dongliang
    Kothare, Prajakti A.
    Trautmann, Michael
    Fineman, Mark
    Taylor, Kristin
    [J]. DIABETES CARE, 2007, 30 (06) : 1487 - 1493
  • [10] The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for type 2 diabetes
    King, P
    Peacock, I
    Donnelly, R
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (05) : 643 - 648